Liu, Baogang

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., et al. (2025) · The Lancet

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 173

ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.

Wang, J., Duan, J., Xing, L., Sun, Y., Guo, W., Wang, H., Chen, J., Han, L., Liu, B., Wang, Q., et al. (2023) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 28

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial

HARMONi-A Study Investigators, Fang, W., Zhao, Y., Luo, Y., Yang, R., Huang, Y., He, Z., Zhao, H., Li, M., Li, K., et al. (2026) · JAMA

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 8